At the heart of influenza virus infectivity lies the membrane fusion process, a critical step where viral and host cell membranes merge, allowing the viral genome to enter host cells and initiate infection. Traditional strategies to inhibit influenza often target viral enzymes or replication machinery, yet these approaches are sometimes thwarted by viral mutation and drug resistance. By contrast, the membrane fusion step represents a highly conserved and indispensable stage of viral entry, making it an attractive target for therapeutic intervention. The current study addresses this by focusing on designed peptides that obstruct fusion, thereby halting infection at its inception.

The research team, led by Kadam, Juraszek, Brandenburg, and colleagues, employed a structure-guided approach that intricately maps the binding loops of V_HH antibodies. These loops have a unique ability to recognize and bind specific viral epitopes with high affinity and selectivity. By isolating the complementary determining region 3 (CDR3) loop from V_HH antibodies known to neutralize influenza virus fusion, the researchers synthesized cyclic peptides that mimic this loop’s conformation and binding properties. The cyclic nature of the peptide confers enhanced stability and resistance to proteolytic degradation, essential attributes for in vivo therapeutic application.

Employing advanced biophysical characterization techniques such as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography, the investigators determined the precise three-dimensional folding and conformational dynamics of the designed macrocycles. This structural rigor allowed them to optimize peptide design for maximal interaction with the influenza hemagglutinin fusion protein (HA), the principal viral surface glycoprotein responsible for mediating membrane fusion. Through iterative cycles of design, synthesis, and testing, the team refined the peptide’s binding affinity, achieving nanomolar potency in fusion inhibition assays.

Functional assays conducted with influenza virus strains revealed that the designed macrocyclic peptide effectively blocks HA-mediated membrane fusion under physiological conditions. The peptide binds to the HA fusion peptide domain, stabilizing it in a pre-fusion conformation and preventing the conformational changes necessary for membrane merger. This mode of action differentiates it from existing fusion inhibitors that typically act post-fusion or indirectly influence viral entry. Moreover, the macrocyclic peptide exhibited broad-spectrum activity across multiple influenza subtypes, an essential feature given the virus’s high antigenic variability.

In addition to in vitro validation, in vivo mouse models infected with lethal doses of influenza virus demonstrated that therapeutic administration of the cyclic peptide dramatically reduced viral titers and improved survival rates. The peptide’s pharmacokinetic profile was favorable, with sustained plasma concentrations and minimal immunogenicity observed. These preclinical data underscore the potential of this synthetic macrocyclic peptide as a viable therapeutic candidate, capable of augmenting or replacing current antiviral regimens that often suffer from resistance and suboptimal efficacy.

One pivotal advantage of using V_HH-derived loops as templates lies in their small size and robust folding, enabling the generation of compact, high-affinity inhibitors that can access recessed viral epitopes typically inaccessible to conventional antibodies. This innovation extends beyond influenza; the conceptual framework can be adapted to engineer macrocyclic peptides targeting fusion proteins of other pathogenic viruses, including coronaviruses and paramyxoviruses. By expanding the reagent toolbox with synthetic peptides precisely modeled on natural antibody loops, a new paradigm in antiviral drug design emerges, merging the specificity of biologics with the chemical versatility of small molecules.

The researchers also highlighted that the macrocyclic peptide’s synthetic origin allows for facile chemical modifications to enhance its properties. Strategies such as conjugation with cell-penetrating moieties, incorporation of non-natural amino acids, or attachment of imaging probes can be employed to further improve its therapeutic index or enable real-time tracking of viral fusion events in live cells. These future directions promise not only therapeutic utility but also a powerful platform for studying viral entry mechanisms at an unprecedented resolution.

This study underscores the importance of structural biology and molecular engineering in contemporary antiviral research. The painstaking elucidation of V_HH antibody loops enabled the rational design of a fusion-inhibiting peptide, breaking free from reliance on large, complex biologics. By distilling the functional essence of antibody binding into a compact macrocyclic structure, the team demonstrated that it is feasible to create stable, potent inhibitors that combine the advantages of peptides and antibodies. This could pave the way toward novel, orally available antiviral drug candidates, overcoming limitations associated with monoclonal antibody therapies.

The membrane fusion blockade achieved by the synthetic peptide also opens the door to combinatorial antiviral strategies. When used alongside neuraminidase inhibitors or polymerase inhibitors, these fusion-targeting compounds can exert synergistic effects, suppressing viral replication through multiple mechanisms simultaneously. This multi-pronged approach could mitigate the emergence of drug-resistant viral strains, a persistent challenge in treating influenza infections and a concern for global public health.

Furthermore, by focusing on the early step of membrane fusion, the peptide inhibitor can function prophylactically to prevent infection or therapeutically to limit viral spread post-exposure. This flexibility enhances its clinical value, particularly in settings of influenza outbreaks where rapid deployment of effective antivirals is critical. Its broad-spectrum activity against diverse influenza subtypes also makes it a promising candidate for pandemic preparedness, addressing the urgent need for versatile therapies capable of countering novel viral strains.

Despite the promise, the researchers acknowledge that translational hurdles remain. Peptide therapeutics often face obstacles related to delivery, stability, and manufacturing scalability. However, the synthetic macrocyclic nature of this inhibitor inherently addresses some of these challenges through improved metabolic stability and ease of chemical synthesis compared to larger biologics. Ongoing studies aim to optimize formulations for inhalable delivery, a targeted approach that could maximize drug concentration at the respiratory epithelium, the primary site of influenza infection, minimizing systemic exposure and potential side effects.

This pioneering work not only advances antiviral therapy but also exemplifies the power of interdisciplinary collaboration, integrating immunology, structural biology, peptide chemistry, and virology. The successful translation of natural antibody features into a synthetic fusion inhibitor heralds a new era where biological principles inform drug design at the molecular level, offering hope for more effective interventions against viral diseases. As influenza continues to pose a global threat, innovations such as this synthetic macrocyclic peptide bring us closer to outmaneuvering the virus and safeguarding public health.

Subject of Research: Influenza virus membrane fusion inhibition via V_HH antibody-inspired synthetic macrocyclic peptides

Article Title: V_HH antibody loop guides design of a synthetic macrocyclic peptide that potently blocks influenza virus membrane fusion

Article References:
Kadam, R.U., Juraszek, J., Brandenburg, B. et al. V_HH antibody loop guides design of a synthetic macrocyclic peptide that potently blocks influenza virus membrane fusion. npj Viruses 3, 83 (2025). https://doi.org/10.1038/s44298-025-00166-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s44298-025-00166-1

Hepatitis B virus is a global health menace, affecting over 250 million people worldwide, with chronic infection leading to serious long-term consequences such as cirrhosis, liver failure, and hepatocellular carcinoma. Conventional treatments, primarily nucleos(t)ide analogues and interferon-based therapies, have been successful in suppressing viral replication but fall short of eradicating the virus entirely due to the persistence of covalently closed circular DNA (cccDNA) in hepatocyte nuclei. This latent reservoir remains a formidable barrier to cure, necessitating lifelong therapy for most patients and the risk of viral reactivation.

The innovative RNAi strategy engineered by Huang, Yang, and colleagues operates by delivering short interfering RNAs (siRNAs) designed to target multiple regions of the HBV genome simultaneously. This multi-target approach ensures a robust and durable knockdown of viral transcripts, including those necessary for the generation of viral proteins and replication intermediates. The ability to diminish the expression of viral antigens like hepatitis B surface antigen (HBsAg) is particularly critical because HBsAg plays a pivotal role in immune evasion and chronicity of infection.

Mechanistically, the therapy exploits the endogenous RNA-induced silencing complex (RISC), which mediates post-transcriptional gene silencing by degrading target mRNAs. Upon administration, the siRNAs are delivered efficiently to hepatocytes via lipid nanoparticle carriers that protect the RNA molecules from degradation and facilitate hepatocyte uptake. Inside the cells, these siRNAs guide RISC to complementary viral RNA sequences, triggering cleavage and abrogation of translation. This molecular precision minimizes off-target effects, a key advantage over broad-spectrum antivirals.

Preclinical data presented in the study highlight significant reductions in serum HBV DNA and HBsAg levels, sustained well beyond the treatment period. Remarkably, the researchers observed that repeated dosing led not only to viral suppression but also to a profound reduction of intrahepatic cccDNA reservoirs. This implies that the RNAi therapeutic might enable immune-mediated clearance mechanisms or prevent replenishment of cccDNA pools, a revolutionary step towards a functional cure.

The immunological impact of the RNAi treatment cannot be overstated. Chronic HBV infection typically results in T-cell exhaustion and an impaired immune response. By reducing the antigenic burden through HBsAg knockdown, the therapy appears to rejuvenate antiviral immunity, as indicated by restored HBV-specific T-cell functionality seen in experimental models. Such immune restoration is critical because it may sustain long-term viral control after cessation of therapy.

The achievement of a functional cure, defined as sustained loss of HBsAg with or without seroconversion to anti-HBs antibodies, has eluded the medical community for decades. This study provides compelling evidence that RNAi therapeutics can bridge that gap by combining potent antiviral activity with immune modulation. Unlike traditional antivirals that require indefinite use, this approach may allow for finite treatment courses, significantly reducing treatment burden and healthcare costs.

Beyond efficacy, the therapeutic design includes safety considerations. The investigational product underwent rigorous toxicity evaluations, with no significant adverse effects detected in animal models. The high specificity of siRNA sequences minimizes the risk of unintended gene silencing, and the delivery system avoids immunogenicity by using biocompatible materials. These findings underscore the translational potential of the RNAi platform for human application.

The implications for global health are profound, especially for regions with high HBV endemicity where access to lifelong antiviral therapy is limited by resource constraints. An RNAi-based curative treatment could revolutionize HBV management paradigms, reduce liver disease burden, and decrease incidence of HBV-related hepatocellular carcinoma, thereby addressing a critical unmet medical need.

Looking forward, the authors of the study are embarking on phase 1/2 clinical trials to evaluate the therapeutic’s safety and efficacy in humans. Optimizing dosing regimens, assessing durability of response, and monitoring emergence of viral resistance are central to these clinical endeavors. Preliminary clinical data from similar RNAi candidates suggest encouraging tolerability and antiviral effects, bolstering optimism for this approach.

This RNAi therapeutic also opens avenues for combinatorial treatment strategies. Pairing it with immune checkpoint inhibitors, therapeutic vaccines, or agents targeting cccDNA stability could synergize to deepen and sustain viral eradication. The modular nature of RNAi design allows for rapid adaptation to viral variants and co-infections, reflecting its versatility as a treatment platform.

In sum, this study heralds a transformative era in HBV therapy, where molecule-level precision editing of viral transcripts by RNA interference could shift the paradigm from viral suppression to viral elimination. As this technology progresses through clinical validation, it holds promise not only to change patient outcomes but also to alleviate the public health burden of chronic hepatitis B worldwide.

The path to a functional cure for HBV has been a protracted journey, but innovations like this RNAi therapeutic provide a beacon of hope. Researchers and clinicians alike eagerly anticipate forthcoming clinical trial results that may confirm the promise of this approach, potentially altering the course of hepatitis B treatment and improving millions of lives.

Subject of Research: Development of RNA interference therapeutics for chronic hepatitis B virus infection aiming for functional cure.

Article Title: An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection.

Article References: Huang, ZA., Yang, Y., Yang, S. et al. An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection. Nat Commun (2025). https://doi.org/10.1038/s41467-025-66876-5

Image Credits: AI Generated

A recent comprehensive real-world cohort study conducted at Xiamen Hospital of TCM evaluated the therapeutic synergy between PEG-IFN α-2b and specific TCM formulations in treating HBeAg-positive CHB patients. The study enrolled 117 patients who were stratified into two groups: one receiving PEG-IFN α-2b monotherapy, and the other receiving the same antiviral regimen supplemented with a customized TCM decoction composed primarily of Licorice, Angelica sinensis, Poria, Paeonia lactiflora, Rhizoma Atractylodis Macrocephalae, Radix Bupleurum Chinense, Mentha piperita, and ginger. The herbal combination was administered consistently for more than six months, allowing assessment of both virological responses and hematologic safety parameters.

The novel integrative treatment arm demonstrated superior clinical outcomes compared to PEG-IFN α-2b alone. Quantitative analyses revealed significantly greater reductions in hepatitis B surface antigen (HBsAg) levels at both 24 and 48 weeks, highlighting improved immune clearance of viral particles. Additionally, the serological conversion rates of hepatitis B e antigen (HBeAg) markedly increased in the combination group, suggesting enhanced immune-mediated viral control. Most notably, by week 48, the group receiving adjunctive TCM exhibited an almost doubled HBV DNA negative conversion rate compared to controls, indicating profound suppression of viral replication.

Mechanistically, PEG-IFN α exerts antiviral effects through induction of innate and adaptive immune responses, including activation of natural killer cells and cytotoxic T lymphocytes. However, its systemic toxicity primarily attributed to bone marrow suppression hampers sustained therapy. The TCM herbal concoction used encompasses bioactive compounds reputed for immunomodulatory, hepatoprotective, and anti-inflammatory properties. For instance, Licorice contains glycyrrhizin, known for its hepatoprotective and anti-fibrotic effects, while Angelica sinensis has immunoregulatory capabilities enhancing cytokine balance. These components likely contribute to not only potentiating antiviral immunity but also mitigating myelosuppression observed in interferon monotherapy.

Safety profiles from the study reinforce the clinical promise of this integrative strategy. Incidence of treatment-associated myelosuppression — which includes significant reductions in white blood cells, red blood cells, and platelets — was substantially lower in patients receiving combined therapy at both mid and end points of treatment assessment. This improvement in hematologic tolerance could lead to better patient adherence and prolonged duration of effective antiviral intervention, a critical factor in achieving sustained virological response in chronic hepatitis B.

This real-world investigation adds to mounting evidence favoring adjunctive TCM approaches in the management of chronic viral hepatitis. Unlike controlled trial settings, real-world studies capture a broader patient demographic and reflect routine clinical practice, thereby enhancing the generalizability of the findings. The methodology entailed meticulous retrospective analysis of etiological markers, liver function tests, and complete blood counts before and after therapy, underscoring the robustness of the data.

Beyond virological and hematological endpoints, the integrative regimen may confer additional hepatoprotective effects through attenuation of liver inflammation and fibrosis progression, potentiated by the complex phytochemical interactions in TCM formulations. This holistic benefit aligns with TCM principles emphasizing systemic balance and immune homeostasis, thereby complementing the targeted actions of PEG-IFN α.

Given the global burden of CHB and the limitations of existing therapeutics, these findings advocate for incorporating traditional medicinal knowledge into mainstream antiviral regimens. While the study opens new avenues for treatment optimization, further randomized controlled trials with larger cohorts and mechanistic explorations are warranted to elucidate precise pathways by which TCM components enhance antiviral efficacy and safety.

In conclusion, the integration of Traditional Chinese Medicine with peginterferon α-2b represents a promising therapeutic advance for HBeAg-positive chronic hepatitis B patients. This combination not only significantly improves antiviral outcomes by increasing serological conversion rates and viral clearance but also importantly reduces adverse myelosuppressive effects, thereby supporting sustained and effective treatment courses. Such strategies may redefine interferon-based therapy paradigms and inspire cross-disciplinary innovations in chronic viral disease management.

The study, recently published in the esteemed journal Future Integrative Medicine, marks an important milestone in bridging ancient medical wisdom with contemporary biochemical interventions. As chronic hepatitis B continues to challenge the medical community, integrative approaches like this offer a beacon of hope for enhancing patient outcomes and quality of life.

Subject of Research: Chronic hepatitis B treatment efficacy and safety enhancement using Traditional Chinese Medicine combined with peginterferon α-2b.

Article Title: Traditional Chinese Medicine Combined with Peginterferon α-2b in Chronic Hepatitis B: A Real-world Cohort Study

News Publication Date: 18-Sep-2025

Web References:

• Future Integrative Medicine journal: https://www.xiahepublishing.com/journal/fim
• DOI link: http://dx.doi.org/10.14218/FIM.2025.00020

Keywords: Chronic hepatitis B, Peginterferon α-2b, Traditional Chinese Medicine, antiviral therapy, serological conversion, myelosuppression, liver inflammation, herbal medicine, immune modulation, HBeAg, HBV DNA, hepatoprotection

HBV remains a formidable global health challenge, infecting over 300 million people worldwide and leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma. Current antiviral therapies, while effective in suppressing viral replication, rarely achieve complete viral eradication, partly due to the virus’s capacity to hide within the host genome and generate diverse forms of viral nucleic acids. Previous studies have highlighted the role of the covalently closed circular DNA (cccDNA), an episomal form of HBV DNA, as a persistent reservoir. However, the extent to which integrated HBV DNA contributes to ongoing viral transcription and clinical outcomes remained unclear until now.

The researchers employed state-of-the-art transcriptomic mapping techniques to dissect the complex interplay between episomal and integrated HBV genomes. Utilizing high-throughput RNA sequencing paired with cutting-edge bioinformatics approaches, they successfully delineated a diverse landscape of HBV transcripts within infected liver tissue samples. This was no small feat, considering the difficulty in distinguishing viral transcripts originated from different genetic contexts within the host genome. Remarkably, the data revealed distinct transcriptomic signatures arising from episomal HBV DNA compared to those integrated into the host chromosomes.

What emerged from this meticulous mapping was a striking heterogeneity in HBV RNA profiles. Episomal HBV, previously regarded as the principal template for viral RNA synthesis, generates canonical transcripts necessary for viral replication. In contrast, integrated HBV DNA—traditionally seen as transcriptionally silent or defective—was now shown to produce a spectrum of aberrant and truncated viral transcripts. These integrated-origin transcripts encompass chimeric human-viral fusion RNAs, which may interfere with normal cellular functions and contribute to oncogenic processes. Importantly, the expression of these variant transcripts holds significant implications for antiviral drug targets and resistance mechanisms.

Drug resistance is a perennial threat to HBV management, often resulting in viral rebound and treatment failure. The study findings imply that HBV genomic integration could serve as a hidden reservoir from which transcriptional diversity fuels resistance evolution. Integrated HBV transcripts lacking critical viral regulatory elements might evade customary viral replication shutdown mechanisms induced by nucleos(t)ide analogues, the backbone of current antiviral regimens. Moreover, production of defective viral proteins from integrated sequences could modulate immune recognition, further complicating therapeutic efficacy.

One particularly groundbreaking aspect of the research is the insight into how HBV transcription from integrated DNA forms is regulated. The study elucidated differential promoter usage and RNA splicing patterns in integrated versus episomal contexts. This reflects a sophisticated viral strategy to modulate gene expression in response to the host environment and antiviral pressures. Such plasticity underscores the challenges in designing drugs that comprehensively target all forms of viral nucleic acids and transcripts, emphasizing the need for novel therapeutics that account for this transcriptomic complexity.

These findings also correlate with clinical observations where HBV-infected patients show varied responses to therapy, including partial suppression, viral breakthrough, or progression to liver cancer despite antiviral treatment. The heterogeneous viral transcriptome mapped by this research provides a plausible mechanistic foundation for such disparities, as different viral populations may harbor distinct susceptibilities or escape pathways under pharmacological stress.

Furthermore, the technological advances demonstrated by this study set a new standard for viral transcriptomics. Employing single-cell transcriptomics combined with long-read sequencing, the researchers mapped the full-length viral RNAs, revealing intricate splice variants and fusion transcripts previously undetectable by conventional methods. This methodological innovation is poised to extend beyond HBV research, offering a powerful toolkit to study other persistent viral infections characterized by genomic integration and transcriptomic variability.

Implications extend beyond the biology of HBV itself. The principles uncovered here concerning integrated viral DNA contributions to transcriptomic heterogeneity and therapy evasion bear relevance to other chronic viral infections, including human immunodeficiency virus (HIV) and human papillomavirus (HPV). These viruses similarly integrate into host genomes and produce diverse transcripts influencing disease progression and therapy outcomes, making the study’s framework broadly applicable.

This newly detailed complexity also beckons a re-evaluation of viral biomarkers employed in clinical monitoring. Conventional assays measuring serum HBV DNA or pregenomic RNA may not fully capture the heterogenous transcriptome landscape, thereby underestimating the viral burden or the presence of drug-resistant populations. Hence, integrating refined transcriptomic assessments could enhance precision medicine approaches for HBV, tailoring antiviral regimens based on comprehensive viral RNA profiling.

Looking ahead, the study opens fertile ground for translational research aimed at targeting integrated HBV DNA transcription or the unique proteins derived from such transcripts. Therapies aimed at silencing these integrated sequences or correcting detrimental host-virus transcript fusions could complement existing nucleos(t)ide analogues, improving the chances for functional cure. Moreover, immunotherapeutic strategies designed to recognize novel viral epitopes expressed from integrated sequences may reinvigorate antiviral immunity in chronic HBV infection.

Beyond the immediate therapeutic implications, these findings prompt broader questions regarding the evolutionary pressures shaping HBV integration and transcriptomic diversity. The study suggests that integration is not merely a dead-end of viral genetics but a dynamic contributor to viral adaptability and persistence. Understanding how the virus exploits integration-driven transcriptional heterogeneity to navigate host defenses and therapeutic challenges will be central to future antiviral innovations.

In conclusion, this landmark study not only unravels the transcriptomic complexity of hepatitis B virus from episomal and integrated DNA but also redefines our comprehension of viral persistence mechanisms and therapeutic resistance. Through sophisticated molecular mapping, the research uncovers a hidden viral reservoir generating diverse transcripts that may undermine current antiviral strategies. As HBV continues to impose a heavy global health burden, insights such as these are pivotal in steering the next generation of targeted and effective treatments, ultimately inching closer to the long-sought goal of HBV eradication.

Subject of Research: The study focuses on mapping the heterogeneity of hepatitis B virus (HBV) transcripts derived from episomal and integrated viral DNA within infected liver tissues and exploring their implications for drug resistance and disease persistence.

Article Title: Episomal and integrated hepatitis B transcriptome mapping uncovers heterogeneity with the potential for drug-resistance.

Article References:
Harris, J.M., Lok, J., Wand, N. et al. Episomal and integrated hepatitis B transcriptome mapping uncovers heterogeneity with the potential for drug-resistance. Nat Commun 16, 8515 (2025). https://doi.org/10.1038/s41467-025-63497-w

Image Credits: AI Generated